Boulay and colleagues analyzed the presence of Smad7 variants in 264 CRC specimens and found that patients with Smad7 deletion had a favorable clinical outcome compared with patients with Smad7 amplification [134]. Here, SMAD7 is linked to colorectal carcinoma.